U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07217184) titled 'Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM' on Oct. 13.
Brief Summary: The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
Study Start Date: July 29, 2021
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: Belantamab mafodotin
Belantamab mafodotin will be admi...